Page last updated: 2024-10-22

alendronate and Neointima

alendronate has been researched along with Neointima in 1 studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Neointima: The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Généreux, P1
Chernin, G1
Assali, AR1
Peruga, JZ1
Robinson, SD1
Schampaert, E1
Bagur, R1
Mansour, S1
Rodés-Cabau, J1
McEntegart, M1
Gerber, R1
L'Allier, P1
de Silva, R1
Daneault, B1
Aggarwal, SK1
Džavík, V1
Ozan, MO1
Ben-Yehuda, O1
Maehara, A1
Stone, GW1
Jonas, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention[NCT02645799]Phase 2270 participants (Anticipated)Interventional2016-04-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for alendronate and Neointima

ArticleYear
Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial.
    American heart journal, 2022, Volume: 249

    Topics: Alendronate; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents;

2022